Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Vaccine is the most important way for fighting against infection diseases. However, multiple injections and unsatisfied immune responses are the main obstacles for current vaccine application. Herein, a dynamic covalent hydrogel (DCH) is used as a single-dose vaccine adjuvant for eliciting robust and sustained humoral immunity. By adjusting the mass ratio of the DCH gel, 10-30 d constant release of the loaded recombinant protein antigens is successfully realized, and it is proved that sustained release of antigens can significantly improve the vaccine efficacy. When loading SARS-CoV-2 RBD (Wuhan and Omicron BA.1 strains) antigens into this DCH gel, an over 32 000 times and 8000 times improvement is observed in antigen-specific antibody titers compared to conventional Aluminum adjuvanted vaccines. The universality of this DCH gel adjuvant is confirmed in a Nipah G antigen test as well as a H1N1 influenza virus antigen test, with much improved protection of C57BL/6 mice against H1N1 virus infection than conventional Aluminum adjuvanted vaccines. This sustainably released, single-dose DCH gel adjuvant provides a new promising option for designing next-generation infection vaccines.

Download full-text PDF

Source
http://dx.doi.org/10.1002/adhm.202400886DOI Listing

Publication Analysis

Top Keywords

dch gel
16
dynamic covalent
8
covalent hydrogel
8
single-dose vaccine
8
vaccine adjuvant
8
humoral immunity
8
conventional aluminum
8
aluminum adjuvanted
8
adjuvanted vaccines
8
gel adjuvant
8

Similar Publications

Vaccine is the most important way for fighting against infection diseases. However, multiple injections and unsatisfied immune responses are the main obstacles for current vaccine application. Herein, a dynamic covalent hydrogel (DCH) is used as a single-dose vaccine adjuvant for eliciting robust and sustained humoral immunity.

View Article and Find Full Text PDF

Structure of biopolymers produced by microalgae plays an important role for their potential biological activity prediction and applications. Previously isolated and well characterized dominant fractions (Dch5-8) from ion-exchange chromatography separation of the biologically active microalga Dictyosphaerium chlorelloides exopolysaccharide (Dch) were pooled and partially acid hydrolyzed. The dominant sugar components in the combined Dch5-8 fraction were Gal and its 2-O-methyl derivative, Rha and Man, all accounting for about 94 mol% of total amount of sugars.

View Article and Find Full Text PDF
Article Synopsis
  • Domestic cat hepadnavirus (DCH) is a new virus discovered in 2018, detected using traditional PCR techniques that are slow and complex.
  • A new real-time PCR (rtPCR) method was developed for faster and more accurate DCH detection, using blood samples directly without the need for DNA extraction.
  • The assay was designed with specific primers, achieving high sensitivity and making it a valuable tool for monitoring and detecting DCH in cats.
View Article and Find Full Text PDF

An NMR weakly-aligning polymer gel has been prepared by copolymerization of acrylonitrile and 2-acrylamide-2-methyl-1-propanesulfonic acid in the presence of 1,4-butanediol diacrylate as a cross-linker. The polymer readily swells in water in a large range of temperatures, although the swelling ratio is decreased in saline solutions. The swollen gel can be mechanically compressed, in a reversible way, generating anisotropy, as easily shown in H NMR experiments, and allowing measurement of D residual dipolar couplings (RDCs) through F1-coupled HSQC experiments.

View Article and Find Full Text PDF

Background And Aims: Lynch syndrome (LS) is the most common cause of hereditary colorectal cancer and is associated with an increased lifetime risk of gastric and duodenal cancers of 8-16% and 7%, respectively; therefore, we aim to describe an esophagogastroduodenoscopy (EGD) surveillance program for upper gastrointestinal (GI) precursor lesions and cancer in LS patients.

Methods: Patients who either had positive genetic testing or met clinical criteria for LS who had a surveillance EGD at our institution from 1996 to 2017 were identified. Patients were included if they had at least two EGDs or an upper GI cancer detected on the first surveillance EGD.

View Article and Find Full Text PDF